GT Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GTBP research report →
Companywww.gtbiopharma.com
GT Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
- CEO
- Michael Martin Breen
- IPO
- 2018
- Employees
- 1
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $4.60M
- P/E
- -0.27
- P/S
- 0.00
- P/B
- 1.73
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -901.32%
- ROIC
- -204.98%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-28,354,000 · -115.42%
- EPS
- $-6.25 · 9.94%
- Op Income
- $-12,422,000
- FCF YoY
- -0.08%
Performance & Tape
- 52W High
- $3.85
- 52W Low
- $0.26
- 50D MA
- $0.39
- 200D MA
- $0.68
- Beta
- 0.64
- Avg Volume
- 1.05M
Get TickerSpark's AI analysis on GTBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 25 | Mun-Gavin David C. | other | 31,250 |
| Sep 4, 25 | Breen Michael Martin | other | 100,000 |
| Sep 4, 25 | URBAN ALAN LOUIS | other | 50,000 |
| Sep 4, 25 | CASAMENTO CHARLES J | other | 62,500 |
| Sep 4, 25 | Kramer Hilary | other | 31,250 |
| Jun 10, 25 | Mun-Gavin David C. | other | 0 |
| May 7, 25 | Kramer Hilary | other | 0 |
| May 8, 25 | Ritter Andrew J | other | 0 |
| Oct 17, 24 | URBAN ALAN LOUIS | other | 23,335 |
| Jun 3, 24 | URBAN ALAN LOUIS | other | 0 |
Our GTBP Coverage
We haven't published any research on GTBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GTBP Report →